等待开盘 02-05 09:30:00 美东时间
+5.360
+1.63%
今日重点评级关注:Canaccord Genuity:维持Wave Life Sciences Ltd."买入"评级,目标价从40美元升至43美元;花旗:维持Palantir Technologies"买入"评级,目标价从235美元升至260美元
02-04 12:15
Barrington Research analyst Gary Prestopino maintains Kadant (NYSE:KAI) with a Outperform and maintains $380 price target.
02-04 01:38
BRIEF-Voestalpine AG - Sells Subsidiary Böhler Profil To Kadant Jan 29 (Reuters) - VOESTALPINE AG VOES.VI : VOESTALPINE AG - TRANSACTION IS EXPECTED TO BE COMPLETED BY THE END OF THE 2025/2026 FINANCIAL YEAR VOESTALPINE AG - SELLS SUBSIDIARY BÖHLER PROFIL TO US INDUSTRIAL COMPANY KADANT INC. Further
01-29 21:30
Kadant Inc. to Acquire voestalpine BÖHLER Profil Kadant Inc. has disclosed plans to acquire voestalpine BÖHLER Profil, a move aimed at enhancing Kadant's position in sustainable industrial processing technologies. The company highlighted anticipated benefits such as improved operational efficiency,
01-29 21:14
Kadant (NYSE:KAI) reported quarterly earnings of $2.59 per share which beat the analyst consensus estimate of $2.18 by 18.75 percent. This is a 8.8 percent decrease over earnings of $2.84 per share from the same period
2025-10-29 05:12
Kadant (NYSE:KAI) is looking for Q4 GAAP EPS of $1.91-$2.11 vs $2.58 analyst estimate..
2025-10-29 05:10
Kadant (NYSE:KAI) affirms FY2025 Adj EPS guidance from $9.05-$9.25 to $9.05-$9.25 vs $9.14 analyst estimate. Raises FY2025 sales outlook from $1.020 billion-$1.040 billion to $1.036 billion-$1.046 billion vs $1.029
2025-10-29 05:09
今日重点评级关注:Guggenheim:上调Neumora Therapeutics评级至"买入",目标价14美元;韦德布什:上调Fate Therapeutics评级至"跑赢大市",目标价从5美元升至7美元
2025-10-28 10:08
Kadant (NYSE:KAI) is set to give its latest quarterly earnings report on Tuesda...
2025-10-28 03:02